亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

蘇州全輝生物科技有限公司  

醫藥原料及中間體生產銷售

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:劉才伙
  • 電話:0512-66368265
  • 郵件:contact@szqhbio.com
  • 傳真:0512-66368287
  • QQ:1259679610
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 格列美脲 CAS號:93479-97-1
格列美脲 CAS號:93479-97-1
單價 面議對比
詢價 暫無
發貨 江蘇蘇州市付款后3天內
過期 長期有效
更新 2016-02-17 09:26
 
詳細信息
 

格列美脲

產品名稱:格列美脲

英文名稱:Glimepiride

化學名:1-[4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基)-乙基]苯磺酰]-3-(反式-4-甲基環己基)-脲

分子式:C24H34N4O5S

分子量:490.62

CAS號:93479-97-1

質量標準:企業標準/WS1-(X-185)-2004Z

性狀:白色或類白色結晶性粉末,無臭,無味

干燥失重:不得超過0.5%

雜志總量:不得超過1.0%

熾灼殘渣:不得超過0.1%

含量:98.0%~102.0%

包裝:25kg;紙板桶/按客戶要求包裝

聯系方式:銷售陳:0512-66368265;18994391946QQ1259679610;contact@szqhbio.*

©2025 蘇州全輝生物科技有限公司 版權所有   技術支持:化工網   訪問量:4704  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |